Pharma Medical News about Nephropathy

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Rationale, design, and baseline characteristics of the Acetylcystein for Contrast-Induced nephropaThy (ACT) Trial: a pragmatic randomized controlled trial to evaluate the efficacy of acetylcysteine for the prevention of contrast-induced nephropathy
Trials, 06/05/09

A large randomized controlled trial (RCT) is needed to provide a reliable answer as to whether acetylcysteine is effective in decreasing the risk of CIN in high-risk patients undergoing angiographic procedures. The mean age was 69, 18% had a baseline serum creatinine >1.5mg/dL, 57% were diabetics and 13% had a history of heart failure. The ongoing ACT Trial is the largest multicentre RCT that will determine whether acetylcysteine is effective in decreasing the risk of CIN in patients at risk undergoing angiography.

<< Previous
Repligen Announces Conference Call of Fourth Quarter and Fiscal...

Next >>
Solvay indupa successfully completes upgrade and expansion of its...

Nephropathy in Type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity
Platelets, 10/30/09 Relevance Score: 91%

Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)
Nephrology Dialysis Transplantation, 10/16/09 Relevance Score: 90%

Renal Cell Carcinoma in Association With IgA Nephropathy in the Elderly
The American Journal of the Medical Sciences, 11/13/09 Relevance Score: 89%

Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetes
Diabetes Care, 10/28/09 Relevance Score: 89%

DNase1 activity in systemic lupus erythematosus patients with and without nephropathy
Rheumatology International, 10/26/09 Relevance Score: 89%